ArticleAdvances in therapy2026
Peripheral and Autonomic Diabetic Neuropathy and Their Additive Risk of Major Adverse Liver Outcomes in Type 2 Diabetes.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionType 2 diabetes (T2D) is a risk factor for the progression of liver disease, particularly relating to metabolic dysfunction-associated steatotic liver disease (MASLD), and consequent major adverse liver outcomes (MALO). Given that diabetic neuropathy reflects advanced metabolic and microvascular injury, we investigated whether somatic and autonomic neuropathy in T2D is associated with MALO.
methodsIn this retrospective cohort study using a large, federated health research network (TriNetX), adults with T2D were stratified into (i) diabetes alone, without coding of neuropathy, (ii) diabetes with peripheral neuropathy coding, (iii) diabetes with autonomic neuropathy coding, and (iv) diabetes with combined peripheral and autonomic neuropathy coding. Propensity score matching was performed to balance demographic, metabolic, and comorbidity profiles. The primary outcome was incident MALO, defined as hepatic decompensation, portal hypertension/stable varices, hepatocellular carcinoma, liver failure, or liver transplantation. Secondary outcomes included individual MALO endpoints, major adverse cardiovascular events (MACE) and all-cause mortality. Cox proportional hazards models were used to estimate hazard ratios (HRs).
resultsAfter matching, a clear gradient was evident between the increased risk of MALO and the presence of neuropathy: peripheral neuropathy and risk of MALO (HR 1.95 [95% CI 1.85, 2.05]), autonomic neuropathy (HR 2.62 [2.52, 2.72]) and combined neuropathy (HR 3.21 [3.03, 3.41]). Associations were consistent across individual MALO endpoints, irrespective of obesity status, and remained significant following temporal washout analyses. Neuropathy also conferred greater risk for MALO compared to other microvascular complications (vs. retinopathy; 2.21 [2.05, 2.39]).
conclusionDiabetic neuropathy is associated with an elevated risk of MALO in T2D. Autonomic, and to a lesser extent peripheral, neuropathy identifies a particularly high-risk phenotype, supporting neuropathic burden as a surrogate marker, and potential driver, of advanced systemic metabolic injury and progressive liver risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.